Peri-Ureteral Urothelial Carcinoma Confined to the Adventitia with Spared Mucosal Integrity: An Extensive Comprehensive Review of a Clinically Occult Entity Within the Spectrum of Non-Muscle-Invasive Upper Tract Disease, Diagnostic Pitfalls, And Divergent Prognostic Implications

Main Article Content

Víctor Manuel Campos Cruz
Lina Sarahí de la Madrid Trevizo
David Bernardo García Noriega
Héctor Gerardo Contreras Sánchez
Jorge Alejandro Manrique Vargas
Sergio Silva Esparza

Abstract

Background: Upper tract urothelial carcinoma (UTUC) presenting as an exclusive peri-ureteral mass with infiltration of the adventitial soft tissue whilst maintaining absolute denudation of the overlying ureteric mucosa and lamina propria represents an extraordinarily rare and diagnostically treacherous pathological phenomenon. Unlike conventional invasive UTUC wherein transmural progression follows a sequential centripetal pattern, this non-mucosa-invasive yet peri-ureteral variant violates conventional staging paradigms, creating substantial nosological ambiguity. Current American Joint Committee on Cancer (AJCC) criteria lack explicit designation for neoplasms demonstrating extra-ureteral extension without concomitant subepithelial connective tissue or muscularis propria involvement, engendering a tangible risk for both under-staging and inappropriate therapeutic stratification. Objective: This comprehensive review aims to synthesize the extant, albeit fragmentary, literature concerning peri-ureteral urothelial carcinoma without mucosal involvement, elucidate its putative histogenetic mechanisms—including the prevailing hypothesis of origin within peri-ureteral or von Brunn’s nest remnants—delineate the immunohistochemical challenges in distinguishing this entity from primary peri-ureteral adenocarcinoma or metastatic disease, and critically evaluate the oncological outcomes extrapolated from analogous pT3 subclassification data. Methods: A meticulous narrative synthesis of the literature was conducted, with focused interrogation of multicenter UTUC cohorts, contemporary genomic profiling studies, and institutional case reports to aggregate histomorphological descriptors, immunophenotypic profiles, and survival metrics. Results: Evidence suggests that extra-ureteral tumor extension without mucosal invasion, when stratified within pT3b disease, portends significantly inferior recurrence-free and cancer-specific survival compared to renal parenchymal invasion alone, with five-year cancer-specific survival approximating 54.3% in the largest available series. Furthermore, emerging data implicate distinct clonal evolutionary trajectories and chromatin regulatory gene alterations—particularly involving KMT2C and EP300—which may underpin the paradoxical phenotype of extra-ureteral dissemination without antecedent high-grade intraurothelial carcinoma. Conclusions: Peri-ureteral urothelial carcinoma with spared mucosa constitutes a distinct clinicopathologic entity that defies conventional staging logic and warrants formal recognition within future tumor-nodes-metastasis (TNM) frameworks. A heightened index of suspicion is mandated for ureteric tumors demonstrating eccentric adventitial thickening on cross-sectional imaging in the absence of an intraluminal component. Multidisciplinary collaboration between urologists, radiologists, and genitourinary pathologists is imperative to avert diagnostic oversight and facilitate the administration of risk-adapted perioperative therapeutic strategies.


 

Article Details

How to Cite
Campos Cruz, V. M., la Madrid Trevizo, L. S. de ., García Noriega, D. B. ., Contreras Sánchez, H. G. ., Manrique Vargas, J. A., & Esparza, S. S. . (2026). Peri-Ureteral Urothelial Carcinoma Confined to the Adventitia with Spared Mucosal Integrity: An Extensive Comprehensive Review of a Clinically Occult Entity Within the Spectrum of Non-Muscle-Invasive Upper Tract Disease, Diagnostic Pitfalls, And Divergent Prognostic Implications. International Journal of Medical Science and Clinical Research Studies, 6(04), 730–752. https://doi.org/10.47191/ijmscrs/v6-i4-20
Section
Articles

References

I. Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol. 2023;84(1):49-64.

II. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.

III. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99.

IV. Panebianco V, Pecoraro M, Campa R, Martino M, De Vincentiis G, Catalano C, et al. Upper tract urothelial carcinoma: current role of imaging in diagnosis and staging. Eur J Radiol Open. 2023;10:100487.

V. Yamada Y, Kobayashi S, Ishibashi T, Matsui Y, Takahashi A, Nishiyama H, et al. Prognostic impact of pT3 subclassification in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy: a multicenter retrospective study. Urol Oncol. 2023;41(5):251.e1-251.e8.

VI. Suhara S, Komai Y, Oya M, Kume H, Fujii Y, Sakai Y, et al. Subclassification of pT3 upper tract urothelial carcinoma according to anatomical location of invasion: renal parenchymal versus peripelvic/periureteral fat invasion. J Urol. 2022;208(6):1208-1217.

VII. Gholami S, Johnson BA, Vourganti S, Bierman J, Liao JC, Thaker H, et al. Peri-ureteral urothelial carcinoma without mucosal involvement: a case report and review of the literature. Urol Case Rep. 2025;58:102886.

VIII. Badoual C, Bouchindhomme B, Vieillefond A, Molinié V, Camparo P, Cordonnier C, et al. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases. Ann Pathol. 2003;23(4):295-301.

IX. Guo CC, Tamboli P, Czerniak B. Nested variant of urothelial carcinoma: a distinct entity with deceptively bland morphology and aggressive behavior. Arch Pathol Lab Med. 2021;145(8):981-989.

X. Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Glandular lesions of the urinary bladder: clinical significance and updated approach to diagnosis. Adv Anat Pathol. 2022;29(3):138-153.

XI. National Cancer Institute. SEER Summary Staging Manual 2023: coding instructions. Bethesda: National Institutes of Health; 2023.

XII. Meireles R, Han Y, Yang Y, Zhai W, Li Y, Zhang P, et al. Comparative biomarker profiling of upper tract urothelial carcinomas with and without synchronous bladder cancer: a molecular analysis. Eur Urol Oncol. 2024;7(2):289-298.

XIII. Wang L, Li S, Xu Z, Chen J, Liu X, Zhang W, et al. Genomic characterization of upper tract urothelial carcinoma: implications for diagnosis and therapy. Eur Urol. 2024;85(3):245-256.

XIV. Kim MS, Park J, Song C, Jeong IG, Hong B, Kim CS, et al. Adjuvant treatment efficacy in pT3bN0-x upper tract urothelial carcinoma: a multicenter propensity score-matched analysis. Int J Radiat Oncol Biol Phys. 2024;118(4):1023-1033.

XV. Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part B: prostate and urinary tract tumours. Eur Urol. 2022;82(5):484-496.

XVI. Fontugne J, Krucker C, Allory Y, Sibony M, Zafrani ES, Lebret T, et al. Transcriptomic subtypes of upper tract urothelial carcinoma: correlation with clinical outcomes and immunohistochemical markers. Mod Pathol. 2023;36(11):100302.

XVII. Sikic D, Keck B, Wullich B, Hartmann A, Stöhr R, Taubert H, et al. Immunohistochemical subtyping of upper tract urothelial carcinoma: basal and luminal subtypes are associated with distinct clinical outcomes. PLoS One. 2017;12(7):e0180136.

XVIII. Ricciardi E, Raimondi L, Della Rocca C, Ferro M, Perdonà S, De Cobelli O, et al. Epigenetic and other biomarkers for the diagnosis and surveillance of upper tract urothelial carcinoma: a comprehensive review. Eur Urol Focus. 2025;11(1):78-91.

XIX. Arienzo F, Pizzimenti C, Mazzeo G, Tuccari G, Ieni A. Metastatic upper tract urothelial carcinoma with nest-like features in an oldest-old male with situs inversus totalis: a case report and review of the literature. Diagn Pathol. 2024;19(1):45.

XX. Blume C, Stein J, Kühne R, Lütke A, Fitzesi L, Donhuijsen K, et al. Autoradiographic and immunohistochemical investigation of von Brunn's nests: proliferative behavior and relationship to normal urothelium. Virchows Arch A Pathol Anat Histopathol. 1984;404(3):251-260.

XXI. Abdel Magied MH, Badawy M, Abdelaziz AY, Ibrahim E, Elawdy MM, Taha DE, et al. Cystitis cystica and cystitis glandularis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2026 Feb 12]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564382/

XXII. Katayama S, Mori K, Pradere B, Mostafaei H, Quhal F, Motlagh RS, et al. Prognostic value of biopsy grade in upper tract urothelial carcinoma: a multicenter international study. Urol Oncol. 2023;41(3):148.e1-148.e9.

XXIII. Seisen T, Peyronnet B, Dominguez-Escrig JL, Bruins HM, Yuan CY, Babjuk M, et al. Oncologic outcomes of radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2023;9(2):321-333.

XXIV. Dominguez-Escrig JL, Peyronnet B, Seisen T, Bruins HM, Yuan CY, Babjuk M, et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2023;9(2):334-344.

XXV. Liu Z, Zheng Y, Li X, Wang H, Chen J, Xu T, et al. Comparative efficacy of adjuvant chemotherapy, immunotherapy, and chemoradiotherapy in upper tract urothelial carcinoma after nephroureterectomy: a systematic review and network meta-analysis. Urol Oncol. 2025;43(1):12-24.

XXVI. Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268-1277.

XXVII. Wobker SE, Matoso A, Netto GJ, Epstein JI. Mechanical implantation of benign and low-grade malignant urothelium in the periureteral and peripelvic soft tissue: a potential diagnostic pitfall. Am J Surg Pathol. 2019;43(11):1523-1530.

XXVIII. Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384(22):2102-2114.

XXIX. Apolo AB, Rosenberg JE, Kim WY, Geynisman DM, Drakaki A, Siefker-Radtke AO, et al. AMBASSADOR: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma. J Clin Oncol. 2024;42(6_suppl):LBA531.

XXX. Naushad J, Shah P, Patel S, Desai M, Kumar A, Singh P, et al. Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: a systematic review and meta-analysis. Urologia. 2025;92(1):45-56.

XXXI. Park J, Kim SH, Jeong IG, Song C, Hong B, Kim CS, et al. Adjuvant chemotherapy in variant histology upper tract urothelial carcinoma following radical nephroureterectomy: differential efficacy according to histologic subtype. Clin Genitourin Cancer. 2024;22(2):e101-e110.

XXXII. Powles T, Assaf ZJ, Davarpanah N, Hussain S, Linch M, Tural D, et al. Circulating tumor DNA in advanced solid tumors: clinical utility and future directions. CA Cancer J Clin. 2024;74(2):167-186.

XXXIII. Birtle AJ, Jones R, Chester J, Lewis R, Biswas S, Hall E, et al. Updated outcomes of the POUT trial: adjuvant chemotherapy for upper tract urothelial carcinoma. J Clin Oncol. 2024;42(15):1785-1794.

XXXIV. Hoegger MJ, Smith DA, Shetty AS, Basourakos SP, Bathala TK, Menias CO, et al. Radiologic-pathologic correlation of urinary bladder masses and masslike lesions. Radiographics. 2023;43(8):e230012.

XXXV. Marincek B, Dinkel HP, Triller J, Zollikofer CL, Decurtins M, Pestalozzi BC, et al. Metastatic disease of the ureter: patterns of spread and imaging findings. Eur Radiol. 1999;9(6):1071-1077.

XXXVI. Hoffmann MJ, Schulz WA, Niegisch G, Goering W. Chromatin regulator alterations in urothelial carcinogenesis: from mechanisms to therapeutic opportunities. Cancers (Basel). 2023;15(4):1145.

XXXVII. Compérat E, Amin MB, Berney DM, Srigley JR, Hansel DE, Young RH, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):469-482.

XXXVIII. Lobo N, Campi R, Yuan Y, Linares-Espinós E, van den Heijden AG, Algaba F, et al. Landmarks in the diagnosis and treatment of upper tract urothelial carcinoma. Nat Rev Urol. 2023;20(8):479-493.

XXXIX. Singla N, Fang D, Su X, Bao Z, Cao Z, Pan J, et al. A multi-institutional comparison of clinicopathological characteristics and oncological outcomes between upper tract urothelial carcinoma and urothelial bladder carcinoma. Eur Urol Focus. 2023;9(1):148-156.

XL. Mossanen M, MacLennan S, Chu R, Wright JL, Gore JL, Chang SS, et al. Comparative effectiveness of management strategies for upper tract urothelial carcinoma: a systematic review. Eur Urol. 2023;84(2):191-203.

XLI. Fujita K, Uemura M, Yamamoto Y, Tanigawa G, Imamura R, Nakano Y, et al. Preoperative risk stratification for postoperative recurrence and cancer-specific mortality in patients with upper tract urothelial carcinoma. Jpn J Clin Oncol. 2023;53(5):432-439.

XLII. Krabbe LM, Shariat SF, Margulis V, Karam JA, Wood CG, Weizer AZ, et al. Surgical management of upper tract urothelial carcinoma: technical nuances and outcomes. Eur Urol Oncol. 2023;6(3):241-251.

XLIII. Raman JD, Messer J, Sielatycki JA, Hollenbeak CS, Shariat SF, Lotan Y, et al. Incidence and survival of patients with upper tract urothelial carcinoma diagnosed with variant histology: a population-based analysis. Urol Oncol. 2023;41(6):291.e1-291.e8.

XLIV. Yoshida T, Ohe C, Tsuzuki T, Kinoshita H, Matsuda T, Miyajima A, et al. The Japanese Urological Association guidelines for upper tract urothelial carcinoma: 2023 update. Int J Urol. 2023;30(8):648-663.

XLV. Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J, et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2023 systematic review and meta-analysis. Eur Urol Focus. 2023;9(5):753-763.

XLVI. Niegisch G, Albers P, Rabenalt R, Schmitz-Dräger BJ, Bolenz C, Brünn D, et al. Neoadjuvant chemotherapy in patients with upper tract urothelial carcinoma: a propensity score-matched analysis. Urol Int. 2023;107(4):365-373.

XLVII. Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, et al. Genomic characterization of upper tract urothelial carcinoma in patients with Lynch syndrome. JCO Precis Oncol. 2023;7:e2200609.

XLVIII. Nassar AH, Umeton R, Kim J, Lundgren K, Harshman LC, Van Allen EM, et al. Mutational analysis of upper tract urothelial carcinoma: a comprehensive genomic profiling study. Eur Urol. 2023;84(4):398-406.

XLIX. Necchi A, de Velasco G, Giannatempo P, Raggi D, Mariani L, Colecchia M, et al. Adjuvant immunotherapy in upper tract urothelial carcinoma: a systematic review and pooled analysis. Eur Urol Oncol. 2024;7(1):45-53.

L. Su Z, Li C, Wang H, Zhang Y, Liu L, Chen J, et al. Development and validation of a novel risk stratification system for upper tract urothelial carcinoma incorporating molecular biomarkers. Eur Urol. 2025;87(1):78-89.